Short Interest in Dominari Holdings Inc. (NASDAQ:DOMH) Expands By 578.3%

Dominari Holdings Inc. (NASDAQ:DOMH) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 15,600 shares, an increase of 578.3% from the March 31st total of 2,300 shares. Based on an average trading volume of 12,300 shares, the short-interest ratio is currently 1.3 days. Currently, 0.3% of the company’s stock are short sold.

Dominari Trading Up 2.2 %

Shares of NASDAQ:DOMH traded up $0.06 during midday trading on Friday, hitting $2.76. The company’s stock had a trading volume of 5,293 shares, compared to its average volume of 11,976. Dominari has a fifty-two week low of $1.76 and a fifty-two week high of $3.67. The stock’s 50 day simple moving average is $2.39 and its 200 day simple moving average is $2.26.

Dominari (NASDAQ:DOMH) last posted its quarterly earnings data on Monday, April 1st. The company reported ($1.28) earnings per share for the quarter. The firm had revenue of $1.01 million during the quarter.

Insider Activity

In other news, President Kyle Michael Wool purchased 8,500 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were bought at an average price of $2.99 per share, with a total value of $25,415.00. Following the completion of the transaction, the president now directly owns 22,750 shares in the company, valued at approximately $68,022.50. The purchase was disclosed in a filing with the SEC, which is available through this link. In the last quarter, insiders have purchased 31,444 shares of company stock valued at $90,278. Insiders own 9.74% of the company’s stock.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.